Exclusive details on Cybin's IND application with the FDA, a move that could make its CYB003 compound the first psilocybin analog to be evaluated in Phase 1/2a development.
Subscribe to:
Post Comments (Atom)
-
Welcome to the weekly edition of Healthcare IT Today Bonus Features . This article will be a weekly roundup of interesting stories, product ...
-
Training artificial intelligence models on more diverse image and data sets can augment decision making, overcome knowledge gaps, and promot...
-
The following is a guest article by Ladd Wiley, Senior Vice President for Global Corporate Affairs, Public Policy, and Advocacy at Epic , ...
No comments:
Post a Comment